| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malaria | 21 | 2026 | 159 | 7.270 |
Why?
|
| Malaria, Vivax | 18 | 2026 | 57 | 5.390 |
Why?
|
| Plasmodium vivax | 18 | 2026 | 56 | 5.120 |
Why?
|
| Trypanosoma cruzi | 30 | 2026 | 54 | 4.960 |
Why?
|
| Antigens, Protozoan | 18 | 2026 | 67 | 3.740 |
Why?
|
| CD8-Positive T-Lymphocytes | 24 | 2026 | 679 | 3.710 |
Why?
|
| Monocytes | 13 | 2026 | 362 | 3.210 |
Why?
|
| Chagas Disease | 21 | 2026 | 38 | 3.190 |
Why?
|
| Toxoplasma | 10 | 2025 | 34 | 2.870 |
Why?
|
| Host-Parasite Interactions | 14 | 2025 | 61 | 2.700 |
Why?
|
| Immunity, Innate | 16 | 2025 | 829 | 2.570 |
Why?
|
| Interferon-gamma | 21 | 2026 | 576 | 2.570 |
Why?
|
| Plasmodium chabaudi | 8 | 2026 | 30 | 2.460 |
Why?
|
| Toxoplasmosis | 8 | 2025 | 21 | 2.450 |
Why?
|
| Plasmodium | 5 | 2025 | 34 | 2.380 |
Why?
|
| Protozoan Vaccines | 12 | 2026 | 16 | 2.320 |
Why?
|
| Dendritic Cells | 9 | 2024 | 534 | 2.230 |
Why?
|
| Leishmaniasis, Visceral | 7 | 2025 | 14 | 2.210 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 4 | 2024 | 34 | 2.100 |
Why?
|
| Malaria, Cerebral | 4 | 2020 | 24 | 2.050 |
Why?
|
| Mice | 65 | 2026 | 11185 | 1.870 |
Why?
|
| Leishmania infantum | 6 | 2025 | 8 | 1.840 |
Why?
|
| Toll-Like Receptors | 9 | 2020 | 434 | 1.790 |
Why?
|
| Animals | 79 | 2026 | 21493 | 1.750 |
Why?
|
| Cytokines | 18 | 2026 | 965 | 1.730 |
Why?
|
| Protozoan Proteins | 10 | 2025 | 137 | 1.670 |
Why?
|
| Antibodies, Protozoan | 16 | 2026 | 59 | 1.630 |
Why?
|
| Inflammation | 11 | 2026 | 1198 | 1.600 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2026 | 605 | 1.570 |
Why?
|
| Leishmaniasis Vaccines | 3 | 2025 | 3 | 1.540 |
Why?
|
| Cancer Vaccines | 4 | 2014 | 51 | 1.530 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2026 | 61 | 1.500 |
Why?
|
| Anopheles | 5 | 2023 | 23 | 1.360 |
Why?
|
| Leishmania | 3 | 2025 | 12 | 1.350 |
Why?
|
| Neutrophils | 4 | 2021 | 396 | 1.340 |
Why?
|
| Mitochondria | 4 | 2026 | 416 | 1.320 |
Why?
|
| Mice, Inbred C57BL | 31 | 2026 | 3506 | 1.320 |
Why?
|
| Plasmodium berghei | 3 | 2019 | 21 | 1.290 |
Why?
|
| Disease Resistance | 4 | 2026 | 27 | 1.250 |
Why?
|
| Mice, Knockout | 22 | 2026 | 2168 | 1.240 |
Why?
|
| Circadian Rhythm | 3 | 2025 | 364 | 1.230 |
Why?
|
| Vaccines, Synthetic | 8 | 2025 | 80 | 1.190 |
Why?
|
| Antibodies, Viral | 6 | 2025 | 329 | 1.180 |
Why?
|
| Antigens, Neoplasm | 4 | 2014 | 134 | 1.180 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2025 | 138 | 1.180 |
Why?
|
| Toll-Like Receptor 9 | 7 | 2014 | 207 | 1.170 |
Why?
|
| Antibodies, Neutralizing | 5 | 2025 | 220 | 1.150 |
Why?
|
| Myeloid Differentiation Factor 88 | 4 | 2022 | 203 | 1.110 |
Why?
|
| Spleen | 10 | 2026 | 476 | 1.100 |
Why?
|
| Malaria, Falciparum | 6 | 2026 | 239 | 1.090 |
Why?
|
| Toll-Like Receptor 7 | 3 | 2013 | 104 | 1.040 |
Why?
|
| Humans | 81 | 2026 | 65845 | 1.020 |
Why?
|
| Energy Metabolism | 3 | 2026 | 400 | 1.010 |
Why?
|
| Adaptive Immunity | 3 | 2025 | 105 | 0.990 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 5 | 2026 | 111 | 0.990 |
Why?
|
| Membrane Transport Proteins | 3 | 2013 | 135 | 0.980 |
Why?
|
| DNA, Protozoan | 7 | 2015 | 51 | 0.970 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2026 | 38 | 0.950 |
Why?
|
| Toxoplasmosis, Ocular | 4 | 2025 | 7 | 0.920 |
Why?
|
| Inflammasomes | 6 | 2026 | 352 | 0.900 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2026 | 642 | 0.890 |
Why?
|
| Plasmodium falciparum | 6 | 2026 | 262 | 0.870 |
Why?
|
| Mice, Inbred BALB C | 12 | 2026 | 869 | 0.870 |
Why?
|
| Membrane Proteins | 6 | 2017 | 926 | 0.850 |
Why?
|
| Reticulocytes | 4 | 2026 | 16 | 0.830 |
Why?
|
| Hypoglycemia | 2 | 2022 | 64 | 0.830 |
Why?
|
| Succinates | 1 | 2024 | 10 | 0.820 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2023 | 441 | 0.820 |
Why?
|
| Coinfection | 2 | 2022 | 59 | 0.760 |
Why?
|
| Superinfection | 1 | 2022 | 12 | 0.750 |
Why?
|
| Female | 47 | 2026 | 34425 | 0.750 |
Why?
|
| Neuraminidase | 7 | 2026 | 47 | 0.750 |
Why?
|
| Toxoplasmosis, Animal | 2 | 2014 | 10 | 0.740 |
Why?
|
| Acidosis, Lactic | 1 | 2022 | 11 | 0.740 |
Why?
|
| Serologic Tests | 3 | 2025 | 34 | 0.720 |
Why?
|
| Erythrocytes | 5 | 2021 | 147 | 0.720 |
Why?
|
| Interleukin-12 | 5 | 2024 | 127 | 0.700 |
Why?
|
| Signal Transduction | 7 | 2026 | 3170 | 0.690 |
Why?
|
| Chagas Cardiomyopathy | 5 | 2021 | 7 | 0.680 |
Why?
|
| Extracellular Traps | 1 | 2021 | 45 | 0.670 |
Why?
|
| Leishmaniasis | 3 | 2016 | 10 | 0.660 |
Why?
|
| Gene Expression Regulation | 7 | 2021 | 1635 | 0.660 |
Why?
|
| Plasmodium yoelii | 1 | 2020 | 6 | 0.650 |
Why?
|
| Parasitemia | 7 | 2026 | 51 | 0.650 |
Why?
|
| Toll-Like Receptor 3 | 3 | 2022 | 66 | 0.640 |
Why?
|
| Lymphocyte Activation | 9 | 2026 | 755 | 0.640 |
Why?
|
| Disease Models, Animal | 11 | 2025 | 2329 | 0.630 |
Why?
|
| Caspase 1 | 4 | 2026 | 115 | 0.630 |
Why?
|
| Caspase 8 | 1 | 2020 | 66 | 0.630 |
Why?
|
| Membrane Glycoproteins | 3 | 2013 | 667 | 0.620 |
Why?
|
| Adjuvants, Immunologic | 7 | 2026 | 238 | 0.610 |
Why?
|
| Immunity | 2 | 2020 | 107 | 0.600 |
Why?
|
| Adenoviridae | 7 | 2026 | 132 | 0.600 |
Why?
|
| Immunization, Secondary | 4 | 2025 | 52 | 0.590 |
Why?
|
| T-Lymphocytes | 5 | 2025 | 1012 | 0.580 |
Why?
|
| Spike Glycoprotein, Coronavirus | 3 | 2025 | 114 | 0.580 |
Why?
|
| Interleukin-1beta | 6 | 2026 | 274 | 0.580 |
Why?
|
| Receptors, Immunologic | 2 | 2014 | 179 | 0.580 |
Why?
|
| Receptors, CCR4 | 1 | 2018 | 4 | 0.570 |
Why?
|
| Brazil | 9 | 2025 | 104 | 0.570 |
Why?
|
| Th2 Cells | 1 | 2018 | 94 | 0.560 |
Why?
|
| Immunization | 5 | 2025 | 135 | 0.550 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2026 | 345 | 0.550 |
Why?
|
| Vaccination | 8 | 2026 | 388 | 0.540 |
Why?
|
| Chromatography, Affinity | 4 | 2026 | 52 | 0.530 |
Why?
|
| Flow Cytometry | 7 | 2019 | 664 | 0.520 |
Why?
|
| Malaria Vaccines | 4 | 2026 | 43 | 0.510 |
Why?
|
| Glycoproteins | 4 | 2026 | 189 | 0.500 |
Why?
|
| Leishmania major | 2 | 2016 | 8 | 0.500 |
Why?
|
| Immunity, Cellular | 3 | 2018 | 170 | 0.500 |
Why?
|
| Inflammation Mediators | 3 | 2020 | 180 | 0.470 |
Why?
|
| Interleukin-10 | 5 | 2025 | 165 | 0.460 |
Why?
|
| Antigen-Antibody Complex | 1 | 2015 | 52 | 0.460 |
Why?
|
| Hemeproteins | 4 | 2022 | 17 | 0.460 |
Why?
|
| Receptors, IgG | 2 | 2021 | 41 | 0.460 |
Why?
|
| Granulocytes | 1 | 2015 | 73 | 0.460 |
Why?
|
| Receptors, CXCR3 | 3 | 2020 | 35 | 0.460 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2021 | 145 | 0.450 |
Why?
|
| Th1 Cells | 5 | 2025 | 171 | 0.450 |
Why?
|
| Transcription, Genetic | 2 | 2018 | 911 | 0.450 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2025 | 20 | 0.440 |
Why?
|
| Male | 30 | 2026 | 31410 | 0.440 |
Why?
|
| Melanoma, Experimental | 2 | 2014 | 43 | 0.440 |
Why?
|
| Leishmania donovani | 2 | 2012 | 4 | 0.440 |
Why?
|
| CTLA-4 Antigen | 1 | 2014 | 73 | 0.430 |
Why?
|
| Nanotubes, Carbon | 1 | 2014 | 19 | 0.420 |
Why?
|
| Interferon Type I | 2 | 2015 | 198 | 0.420 |
Why?
|
| Biological Evolution | 2 | 2020 | 129 | 0.410 |
Why?
|
| Leishmaniasis, Cutaneous | 2 | 2016 | 17 | 0.410 |
Why?
|
| Epitopes, B-Lymphocyte | 2 | 2011 | 18 | 0.410 |
Why?
|
| Immunoglobulin G | 8 | 2026 | 472 | 0.410 |
Why?
|
| Parasites | 3 | 2022 | 15 | 0.400 |
Why?
|
| Interleukin-12 Subunit p40 | 3 | 2021 | 18 | 0.400 |
Why?
|
| Liver | 4 | 2026 | 875 | 0.400 |
Why?
|
| Brain | 3 | 2020 | 1672 | 0.400 |
Why?
|
| Nucleic Acids | 2 | 2013 | 67 | 0.390 |
Why?
|
| Nanotechnology | 1 | 2014 | 139 | 0.390 |
Why?
|
| Asymptomatic Infections | 2 | 2025 | 29 | 0.390 |
Why?
|
| Carrier Proteins | 3 | 2014 | 719 | 0.390 |
Why?
|
| Cells, Cultured | 8 | 2021 | 2194 | 0.380 |
Why?
|
| Toxoplasmosis, Congenital | 1 | 2012 | 4 | 0.380 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2012 | 26 | 0.370 |
Why?
|
| Immunophenotyping | 5 | 2018 | 194 | 0.370 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2026 | 186 | 0.360 |
Why?
|
| Bacterial Infections | 1 | 2014 | 151 | 0.360 |
Why?
|
| Drug Carriers | 1 | 2014 | 190 | 0.360 |
Why?
|
| Immunotherapy | 1 | 2014 | 274 | 0.360 |
Why?
|
| Antigens, CD | 4 | 2026 | 344 | 0.360 |
Why?
|
| Interleukin-17 | 1 | 2012 | 101 | 0.360 |
Why?
|
| Reactive Oxygen Species | 3 | 2026 | 238 | 0.350 |
Why?
|
| Phagocytosis | 4 | 2021 | 257 | 0.350 |
Why?
|
| Vaccines | 2 | 2023 | 97 | 0.340 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 37 | 0.340 |
Why?
|
| Hydrocarbons, Aromatic | 1 | 2011 | 2 | 0.340 |
Why?
|
| Adult | 18 | 2026 | 17579 | 0.340 |
Why?
|
| Orthomyxoviridae | 2 | 2013 | 29 | 0.330 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 4 | 2026 | 263 | 0.330 |
Why?
|
| Iron | 2 | 2022 | 156 | 0.330 |
Why?
|
| Cell Differentiation | 5 | 2021 | 1391 | 0.330 |
Why?
|
| Chemokines | 2 | 2021 | 99 | 0.320 |
Why?
|
| Young Adult | 10 | 2025 | 4883 | 0.310 |
Why?
|
| Disease Susceptibility | 3 | 2019 | 170 | 0.310 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 518 | 0.310 |
Why?
|
| Glucose | 2 | 2026 | 478 | 0.300 |
Why?
|
| Nanoparticles | 2 | 2026 | 553 | 0.300 |
Why?
|
| Reactive Nitrogen Species | 2 | 2026 | 9 | 0.300 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2025 | 449 | 0.300 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2025 | 63 | 0.300 |
Why?
|
| Cell Separation | 3 | 2019 | 147 | 0.290 |
Why?
|
| Genetic Vectors | 6 | 2014 | 930 | 0.290 |
Why?
|
| Proteomics | 1 | 2011 | 299 | 0.290 |
Why?
|
| Glycolysis | 2 | 2026 | 59 | 0.280 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2023 | 248 | 0.280 |
Why?
|
| Epitope Mapping | 1 | 2008 | 52 | 0.280 |
Why?
|
| NF-kappa B | 2 | 2018 | 436 | 0.270 |
Why?
|
| Dog Diseases | 1 | 2008 | 47 | 0.270 |
Why?
|
| Recombinant Proteins | 5 | 2025 | 710 | 0.260 |
Why?
|
| Lysosomes | 1 | 2008 | 176 | 0.260 |
Why?
|
| Dogs | 4 | 2019 | 326 | 0.260 |
Why?
|
| Protozoan Infections | 1 | 2006 | 3 | 0.250 |
Why?
|
| Squalene | 1 | 2026 | 2 | 0.250 |
Why?
|
| Macrophages, Peritoneal | 3 | 2021 | 75 | 0.250 |
Why?
|
| Eukaryota | 1 | 2006 | 31 | 0.240 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2026 | 52 | 0.240 |
Why?
|
| Phosphate-Binding Proteins | 1 | 2026 | 20 | 0.230 |
Why?
|
| Middle Aged | 13 | 2025 | 18501 | 0.230 |
Why?
|
| Pneumococcal Vaccines | 1 | 2025 | 22 | 0.230 |
Why?
|
| Macrophages | 4 | 2016 | 1042 | 0.230 |
Why?
|
| Pneumococcal Infections | 1 | 2025 | 39 | 0.230 |
Why?
|
| Hepatitis D | 1 | 2025 | 2 | 0.230 |
Why?
|
| Hepatitis Antibodies | 1 | 2025 | 6 | 0.220 |
Why?
|
| Hepatitis Delta Virus | 1 | 2025 | 3 | 0.220 |
Why?
|
| Orthobunyavirus | 1 | 2025 | 1 | 0.220 |
Why?
|
| Bunyaviridae Infections | 1 | 2025 | 2 | 0.220 |
Why?
|
| Astrocytes | 1 | 2026 | 123 | 0.220 |
Why?
|
| Point-of-Care Testing | 1 | 2025 | 41 | 0.220 |
Why?
|
| Travel | 1 | 2025 | 44 | 0.220 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2017 | 112 | 0.210 |
Why?
|
| Heart | 3 | 2021 | 298 | 0.210 |
Why?
|
| Viral Vaccines | 2 | 2022 | 56 | 0.210 |
Why?
|
| Influenza Vaccines | 1 | 2025 | 100 | 0.210 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2024 | 7 | 0.210 |
Why?
|
| RNA, Protozoan | 2 | 2014 | 10 | 0.200 |
Why?
|
| Myocardium | 2 | 2019 | 302 | 0.200 |
Why?
|
| Interferon Regulatory Factors | 1 | 2024 | 43 | 0.200 |
Why?
|
| Neoplasms | 1 | 2014 | 1378 | 0.200 |
Why?
|
| Cricetinae | 1 | 2024 | 362 | 0.200 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2022 | 351 | 0.200 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 144 | 0.200 |
Why?
|
| Polylysine | 1 | 2024 | 49 | 0.200 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 60 | 0.200 |
Why?
|
| Lipopolysaccharides | 2 | 2020 | 625 | 0.200 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2025 | 503 | 0.200 |
Why?
|
| DNA, Mitochondrial | 1 | 2024 | 89 | 0.200 |
Why?
|
| Cell Death | 2 | 2022 | 289 | 0.190 |
Why?
|
| Acute Disease | 4 | 2020 | 665 | 0.190 |
Why?
|
| Mice, Transgenic | 2 | 2024 | 1292 | 0.190 |
Why?
|
| Kupffer Cells | 1 | 2022 | 43 | 0.190 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2020 | 62 | 0.190 |
Why?
|
| Nucleocapsid | 1 | 2022 | 12 | 0.190 |
Why?
|
| Gluconeogenesis | 1 | 2022 | 15 | 0.190 |
Why?
|
| Adolescent | 7 | 2025 | 6368 | 0.180 |
Why?
|
| Nucleocapsid Proteins | 1 | 2022 | 34 | 0.180 |
Why?
|
| Lipids | 1 | 2025 | 331 | 0.180 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2022 | 81 | 0.180 |
Why?
|
| B-Lymphocytes | 2 | 2017 | 565 | 0.180 |
Why?
|
| Antimalarials | 1 | 2023 | 131 | 0.180 |
Why?
|
| Vaccines, Inactivated | 1 | 2021 | 14 | 0.180 |
Why?
|
| Cell Phone | 1 | 2022 | 42 | 0.180 |
Why?
|
| Blood | 1 | 2021 | 31 | 0.180 |
Why?
|
| GPI-Linked Proteins | 1 | 2021 | 38 | 0.170 |
Why?
|
| Cell Proliferation | 3 | 2018 | 1044 | 0.170 |
Why?
|
| Shock, Septic | 2 | 2014 | 89 | 0.170 |
Why?
|
| Cohort Studies | 2 | 2021 | 2651 | 0.170 |
Why?
|
| Interleukins | 1 | 2021 | 89 | 0.170 |
Why?
|
| RNA, Messenger | 2 | 2025 | 1583 | 0.170 |
Why?
|
| Cell Adhesion Molecules | 1 | 2021 | 95 | 0.170 |
Why?
|
| Seasons | 1 | 2021 | 140 | 0.170 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2021 | 11 | 0.170 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2021 | 8 | 0.170 |
Why?
|
| Chorioretinitis | 1 | 2020 | 2 | 0.160 |
Why?
|
| Lymphocyte Count | 2 | 2018 | 71 | 0.160 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 2012 | 34 | 0.160 |
Why?
|
| Rats | 1 | 2024 | 2005 | 0.160 |
Why?
|
| CpG Islands | 2 | 2014 | 219 | 0.160 |
Why?
|
| Neutrophil Activation | 1 | 2020 | 23 | 0.160 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 23 | 0.160 |
Why?
|
| Societies, Scientific | 1 | 2020 | 36 | 0.160 |
Why?
|
| Granzymes | 2 | 2021 | 22 | 0.160 |
Why?
|
| International Cooperation | 1 | 2020 | 87 | 0.160 |
Why?
|
| Chemokine CCL3 | 1 | 2020 | 8 | 0.160 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 110 | 0.160 |
Why?
|
| Blotting, Western | 2 | 2011 | 611 | 0.160 |
Why?
|
| Sensitivity and Specificity | 4 | 2026 | 1172 | 0.160 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 74 | 0.160 |
Why?
|
| Allergy and Immunology | 1 | 2019 | 8 | 0.150 |
Why?
|
| Enzyme Activation | 1 | 2020 | 391 | 0.150 |
Why?
|
| Adenovirus Vaccines | 1 | 2019 | 1 | 0.150 |
Why?
|
| Blood Glucose | 1 | 2022 | 502 | 0.150 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 148 | 0.150 |
Why?
|
| Intestines | 1 | 2021 | 184 | 0.150 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 160 | 0.150 |
Why?
|
| Antigens | 2 | 2022 | 145 | 0.140 |
Why?
|
| Trophozoites | 1 | 2018 | 6 | 0.140 |
Why?
|
| Alleles | 2 | 2026 | 455 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 542 | 0.140 |
Why?
|
| Fibroblasts | 1 | 2020 | 423 | 0.140 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2018 | 64 | 0.140 |
Why?
|
| Carbohydrate Metabolism | 1 | 2018 | 49 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2018 | 62 | 0.140 |
Why?
|
| Species Specificity | 2 | 2026 | 344 | 0.140 |
Why?
|
| RNA-Binding Proteins | 2 | 2018 | 446 | 0.130 |
Why?
|
| Mosquito Vectors | 3 | 2022 | 17 | 0.130 |
Why?
|
| Leukocytes | 1 | 2018 | 110 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 206 | 0.130 |
Why?
|
| Eating | 1 | 2018 | 140 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.130 |
Why?
|
| Genotype | 2 | 2025 | 676 | 0.130 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2018 | 206 | 0.130 |
Why?
|
| Chemokine CXCL9 | 1 | 2016 | 23 | 0.120 |
Why?
|
| Survival Analysis | 3 | 2021 | 579 | 0.120 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 56 | 0.120 |
Why?
|
| Receptors, CCR5 | 1 | 2016 | 59 | 0.120 |
Why?
|
| CD36 Antigens | 1 | 2016 | 26 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 223 | 0.120 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2016 | 42 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2018 | 398 | 0.120 |
Why?
|
| Injections, Intramuscular | 2 | 2026 | 72 | 0.120 |
Why?
|
| Perforin | 1 | 2016 | 26 | 0.120 |
Why?
|
| Phenotype | 3 | 2019 | 1236 | 0.120 |
Why?
|
| Gene Expression Profiling | 4 | 2017 | 799 | 0.120 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 134 | 0.110 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2016 | 84 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 691 | 0.110 |
Why?
|
| Endocytosis | 1 | 2016 | 152 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 169 | 0.110 |
Why?
|
| Protein Multimerization | 1 | 2015 | 181 | 0.110 |
Why?
|
| Antigen Presentation | 2 | 2026 | 239 | 0.110 |
Why?
|
| Parasite Load | 1 | 2014 | 4 | 0.110 |
Why?
|
| Mice, Mutant Strains | 2 | 2016 | 301 | 0.110 |
Why?
|
| Adenoviruses, Human | 1 | 2014 | 10 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2016 | 220 | 0.110 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2014 | 24 | 0.110 |
Why?
|
| Macaca | 1 | 2014 | 30 | 0.110 |
Why?
|
| Calibration | 1 | 2014 | 69 | 0.110 |
Why?
|
| Insulin | 1 | 2018 | 697 | 0.100 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 240 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2014 | 33 | 0.100 |
Why?
|
| Immune Tolerance | 1 | 2015 | 187 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2739 | 0.100 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 139 | 0.100 |
Why?
|
| Cats | 1 | 2014 | 92 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2019 | 377 | 0.100 |
Why?
|
| Biosynthetic Pathways | 1 | 2013 | 17 | 0.100 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2013 | 24 | 0.100 |
Why?
|
| Insect Vectors | 1 | 2013 | 15 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2025 | 745 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 282 | 0.100 |
Why?
|
| Lymphocytes | 1 | 2014 | 210 | 0.100 |
Why?
|
| Genome, Insect | 1 | 2013 | 40 | 0.100 |
Why?
|
| Peru | 2 | 2022 | 7 | 0.090 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 279 | 0.090 |
Why?
|
| Dimerization | 1 | 2013 | 145 | 0.090 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2012 | 5 | 0.090 |
Why?
|
| Oxygen | 1 | 2014 | 323 | 0.090 |
Why?
|
| Computational Biology | 2 | 2013 | 369 | 0.090 |
Why?
|
| Superoxides | 1 | 2012 | 73 | 0.090 |
Why?
|
| Th17 Cells | 1 | 2012 | 65 | 0.090 |
Why?
|
| Haplotypes | 1 | 2012 | 137 | 0.090 |
Why?
|
| Chemotaxis | 1 | 2012 | 51 | 0.090 |
Why?
|
| CD4 Antigens | 1 | 2013 | 149 | 0.090 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2021 | 219 | 0.090 |
Why?
|
| Cytoskeletal Proteins | 1 | 2013 | 204 | 0.090 |
Why?
|
| Aged | 4 | 2021 | 15147 | 0.090 |
Why?
|
| fas Receptor | 1 | 2012 | 56 | 0.090 |
Why?
|
| Immunologic Memory | 1 | 2014 | 284 | 0.090 |
Why?
|
| AT Rich Sequence | 1 | 2011 | 5 | 0.090 |
Why?
|
| Emulsions | 2 | 2026 | 501 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 77 | 0.090 |
Why?
|
| Macaca mulatta | 1 | 2012 | 263 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2018 | 2090 | 0.080 |
Why?
|
| Child | 3 | 2020 | 4653 | 0.080 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 89 | 0.080 |
Why?
|
| Immunoassay | 1 | 2011 | 71 | 0.080 |
Why?
|
| Virulence Factors | 2 | 2022 | 86 | 0.080 |
Why?
|
| Vaccines, DNA | 3 | 2019 | 98 | 0.080 |
Why?
|
| Peptides | 1 | 2014 | 593 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 99 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2010 | 202 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 233 | 0.080 |
Why?
|
| Macrophage Activation | 1 | 2010 | 115 | 0.080 |
Why?
|
| Transfection | 1 | 2011 | 700 | 0.080 |
Why?
|
| Antigen-Presenting Cells | 1 | 2010 | 180 | 0.080 |
Why?
|
| Oligonucleotides | 1 | 2011 | 229 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 793 | 0.070 |
Why?
|
| Phylogeny | 2 | 2025 | 400 | 0.070 |
Why?
|
| Fever | 1 | 2009 | 67 | 0.070 |
Why?
|
| Leukocyte Count | 1 | 2008 | 102 | 0.070 |
Why?
|
| Melanoma | 1 | 2012 | 335 | 0.070 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2008 | 27 | 0.070 |
Why?
|
| Cell Line | 2 | 2013 | 2031 | 0.070 |
Why?
|
| Retroelements | 1 | 2008 | 44 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 237 | 0.070 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2008 | 242 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 1573 | 0.060 |
Why?
|
| Administration, Intranasal | 1 | 2026 | 29 | 0.060 |
Why?
|
| Life Cycle Stages | 1 | 2026 | 21 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2026 | 37 | 0.060 |
Why?
|
| Drug Stability | 1 | 2026 | 145 | 0.060 |
Why?
|
| Cross Reactions | 1 | 2026 | 140 | 0.060 |
Why?
|
| Genes, Protozoan | 2 | 2017 | 14 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2026 | 225 | 0.060 |
Why?
|
| CD40 Ligand | 1 | 2026 | 159 | 0.060 |
Why?
|
| Lectins, C-Type | 1 | 2026 | 80 | 0.060 |
Why?
|
| Vaccines, Combined | 1 | 2025 | 9 | 0.060 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2025 | 91 | 0.060 |
Why?
|
| Pyroptosis | 1 | 2026 | 38 | 0.060 |
Why?
|
| Hepatitis delta Antigens | 1 | 2025 | 2 | 0.060 |
Why?
|
| Streptococcus pneumoniae | 1 | 2025 | 67 | 0.060 |
Why?
|
| Travel-Related Illness | 1 | 2025 | 5 | 0.060 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2025 | 18 | 0.060 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2026 | 143 | 0.060 |
Why?
|
| Time Factors | 1 | 2013 | 3779 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 1590 | 0.050 |
Why?
|
| Sepsis | 1 | 2009 | 309 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 1980 | 0.050 |
Why?
|
| Cell Movement | 2 | 2020 | 484 | 0.050 |
Why?
|
| Liposomes | 1 | 2025 | 118 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2025 | 181 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2025 | 292 | 0.050 |
Why?
|
| Mutation | 1 | 2013 | 2675 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2008 | 1161 | 0.050 |
Why?
|
| Poly I-C | 1 | 2024 | 76 | 0.050 |
Why?
|
| Genome, Viral | 1 | 2025 | 145 | 0.050 |
Why?
|
| Transcriptome | 2 | 2021 | 408 | 0.050 |
Why?
|
| Primaquine | 1 | 2023 | 4 | 0.050 |
Why?
|
| Chloroquine | 1 | 2023 | 56 | 0.050 |
Why?
|
| Rabbits | 1 | 2024 | 342 | 0.050 |
Why?
|
| Epitopes | 1 | 2024 | 291 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2004 | 326 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 25 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2026 | 1294 | 0.050 |
Why?
|
| Convalescence | 1 | 2022 | 17 | 0.040 |
Why?
|
| Cross Protection | 1 | 2021 | 6 | 0.040 |
Why?
|
| Mucins | 1 | 2022 | 27 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2022 | 126 | 0.040 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2022 | 48 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 432 | 0.040 |
Why?
|
| ROC Curve | 1 | 2022 | 295 | 0.040 |
Why?
|
| Phagosomes | 1 | 2021 | 44 | 0.040 |
Why?
|
| Butyrophilins | 1 | 2021 | 3 | 0.040 |
Why?
|
| Immunological Synapses | 1 | 2021 | 9 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 80 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2009 | 1561 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 230 | 0.040 |
Why?
|
| Apoptosis | 2 | 2019 | 1100 | 0.040 |
Why?
|
| Sirolimus | 1 | 2021 | 93 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2022 | 267 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 26 | 0.040 |
Why?
|
| Galactosyltransferases | 1 | 2020 | 15 | 0.040 |
Why?
|
| Community-Institutional Relations | 1 | 2020 | 42 | 0.040 |
Why?
|
| Mammals | 1 | 2022 | 222 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 133 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 2020 | 32 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2020 | 42 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2020 | 30 | 0.040 |
Why?
|
| Boston | 1 | 2021 | 259 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2021 | 223 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2025 | 741 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 301 | 0.040 |
Why?
|
| Receptors, CCR2 | 1 | 2019 | 13 | 0.040 |
Why?
|
| Circadian Clocks | 1 | 2020 | 46 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 106 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 181 | 0.040 |
Why?
|
| Myocarditis | 1 | 2020 | 68 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2018 | 16 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2020 | 283 | 0.040 |
Why?
|
| Consensus | 1 | 2019 | 175 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.030 |
Why?
|
| Ligands | 1 | 2019 | 414 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2020 | 346 | 0.030 |
Why?
|
| Gene Expression | 1 | 2021 | 856 | 0.030 |
Why?
|
| Gene Ontology | 1 | 2017 | 38 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 332 | 0.030 |
Why?
|
| Virulence | 1 | 2017 | 199 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2020 | 556 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 489 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 969 | 0.030 |
Why?
|
| Leishmania mexicana | 1 | 2016 | 8 | 0.030 |
Why?
|
| Vacuoles | 1 | 2016 | 31 | 0.030 |
Why?
|
| Heme | 1 | 2016 | 30 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 2500 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1148 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 211 | 0.030 |
Why?
|
| Immune System Phenomena | 1 | 2015 | 3 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2016 | 165 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 514 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 408 | 0.030 |
Why?
|
| Histones | 1 | 2018 | 497 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2014 | 10 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 663 | 0.030 |
Why?
|
| Synteny | 1 | 2013 | 24 | 0.020 |
Why?
|
| Genetic Complementation Test | 1 | 2013 | 67 | 0.020 |
Why?
|
| Genes, Essential | 1 | 2013 | 20 | 0.020 |
Why?
|
| Chromosomes, Insect | 1 | 2013 | 10 | 0.020 |
Why?
|
| Insecticide Resistance | 1 | 2013 | 11 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2014 | 312 | 0.020 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2013 | 66 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 3340 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2013 | 40 | 0.020 |
Why?
|
| Insect Proteins | 1 | 2013 | 83 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2013 | 103 | 0.020 |
Why?
|
| Molecular Sequence Annotation | 1 | 2013 | 67 | 0.020 |
Why?
|
| Insecticides | 1 | 2013 | 45 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 152 | 0.020 |
Why?
|
| Infant | 1 | 2018 | 1718 | 0.020 |
Why?
|
| Drosophila | 1 | 2016 | 480 | 0.020 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2012 | 10 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 297 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2013 | 180 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2013 | 312 | 0.020 |
Why?
|
| DNA Transposable Elements | 1 | 2013 | 160 | 0.020 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2011 | 33 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2012 | 123 | 0.020 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2011 | 54 | 0.020 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2011 | 98 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2013 | 396 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 351 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 5475 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1226 | 0.020 |
Why?
|